Introduction {#Sec1}
============

Juvenile myelomonocytic leukemia (JMML) is a rare, early childhood neoplasm with features characteristic of both myelodysplastic and myeloproliferative disorders. Most JMML cases are severe, with the only curative treatment being hematopoietic stem cell transplantation (HSCT) \[[@CR1], [@CR4]\]. However, clinical evolution is heterogeneous, with occasional transformation to acute myeloid leukemia (AML) and frequent relapses after HSCT, whereas some rare "long-term survivors" experience spontaneous remission and survive without treatment \[[@CR3], [@CR4], [@CR16]\]. The management of patients with JMML requires accurate assessment of genetic and clinical features to help in patient risk stratification \[[@CR2], [@CR5]\]. We hypothesized that complete genomic characterization of JMML would aid in distinguishing these cases.

Driver mutations converge on the RAS-signaling pathway. Mutations in *NF1*, *NRAS*, *KRAS*, *PTPN11*, and *CBL* currently allow for a molecular diagnosis in 85% of patients \[[@CR14], [@CR15], [@CR23]\]. Recently, secondary mutations, such as *SETBP1* and *JAK3*, were identified in a number of patients with JMML at diagnosis \[[@CR20]\]. We therefore sequenced a series of genes involved in signal transduction, splicing, transcription, and epigenetic modification, in addition to the canonical RAS genes. These findings uncovered a level of genetic complexity in JMML.

Methods {#Sec2}
=======

Patient samples {#Sec3}
---------------

This study included 93 patients with JMML, diagnosed from 2009 to 2018 at the Department of Hematology and Oncology, Shanghai Children's Medical Center (SCMC), China. All patients harboring gene alterations were diagnosed according to WHO criteria for the diagnosis of JMML.

Targeted NGS {#Sec4}
------------

Genomic DNA was extracted from total peripheral blood (PB) in 68 cases or bone marrow (BM) aspirates in 25 cases at diagnosis, and 500  ng of DNA were fragmented on the Covaris M220 Focused-ultrasonicator and purified to yield fragments of 450--550 bp. Fragmented DNA was modified by end-repair, 3′ end adenylylation and Illumina adaptor ligation. The adapter-ligated DNA fragments were captured by a customized panel of biotinylated oligoprobes (Roche NimbleGen) and amplified. Amplified material was validated and quantified using an Agilent 2100 Bioanalyzer. Each DNA library was then sequenced on an Illumina X Ten for paired-end reads at 150 bp by the targeted gene panel designed (Table [1](#Tab1){ref-type="table"}), which was designed to cover the RAS-signaling gene regions and the possible synergistic gene regions involved in signal transduction, splicing, transcription, and epigenetic modification. Genetic analysis in non-hematopoietic tissues (such as fingernails, hair follicles, or buccal swab samples) of patients or PB of the patients' parents was of critical importance in addition to the screening in leukemic cells to determine whether the mutation was somatic or germline, considering the milder clinical course described in germline mutations. When potential leukocyte contamination in hair follicles or buccal swab samples existed, fingernails or the parents' samples were done.Table 1Genes involved in the panel screening the samples with JMMLRAS-signaling GeneSignal transductionTranscription factorEpigenetic modifierSplicesome*CBLSETBP1GATA2ASXL1SRSF2NF1NOTCH1RUNX1EZH2ZRSR2NRASJAK2CEBPADNMT3AU2AF1KRASJAK3ETV6FLT3SF3B1PTPN11CSF3RFOXN1KDM6AHRASARHGAP26TERTNF2IDH1TERCMLLT11TET2MPLTP53NPM1SH2B3PDGFRBRABEP1ROBO1ROBO2HEPACAM2*

Bioinformatics {#Sec5}
--------------

The raw FASTQ data were trimmed, filtering the low quality or undefined bases, and deleting the reads that has a length less than 50 bp. The clean reads were then aligned to the hg19 reference genome using the BWA-MEM (BWA-0.7.10). Duplicates were removed using Picard. BAM files were further processed according to Genome Analysis Toolkit best practices (<https://www.broadinstitute.org/gatk/guide/bp_step.php?p=1>), by performing Indel Realignment and Base Quality Recalibration. Variants were called using VarScan 2 and the variants were annotated using ANNOVAR. The final output positive mutations were confirmed by using the Sanger sequencing method.

Statistical analysis {#Sec6}
--------------------

Patients' outcome data updated on December 31, 2018, were used. Event-free survival (EFS) time was calculated from diagnosis to the first failure, including death, relapse, or treatment abandonment due to disease progression. Overall survival (OS) time was considered from the time of diagnosis to death. When no events occurred, the observation was censored at the time of last follow-up. EFS and OS curves were estimated by the Kaplan-Meier method and compared with the log-rank test. Univariable and multivariable analyses were performed using the Cox model. The chi-square test was used to assess the associations and distribution characteristics between categorical variables. All *P* values were 2-sided, with values of \< 0.05 indicating statistical significance. For statistical analysis, we used the SPSS Mac23.0.0 (IBM Corp.) software package.

Results {#Sec7}
=======

Clinical and biological features at diagnosis {#Sec8}
---------------------------------------------

In the 93 cases, the median age of diagnosis was 32.6 (range, 3.3--168.0) months, 50 cases were less than 24 months, 61 cases were male, and 32 were female. White blood cells' number at diagnosis was 29.2 (2.7--127.1) × 10^3^/μL, platelet count was 73.3 (4.0--357.0) × 10^3^/μL, and monocytes' number was 5.2 (1.1--48.1) × 10^3^/μL. Percentage of myeloid and erythroid precursors on PB smear was 5.0 (0--24.0)%. Median percentage of BM blasts was 7.8 (0.4--20.0)%.

There were 30 cases with *PTPN11* mutation, 20 with *NF1* mutation, 16 with *NRAS* mutation, 10 with *KRAS* mutation, 4 with *CBL* mutation, and 13 with other mutations unable to be simply categorized to the five classical RAS-signaling mutations aforementioned (Table [2](#Tab2){ref-type="table"}). In these cases, there were 89 somatic mutations and only 4 germline mutations, including 2 *NF1*, 1 *PTPN11*, and 1 *KRAS* mutation.Table 2Characteristics of patients with JMMLVariableValueTotal cases (*N*)Gender (male/female)61/3293Median age at diagnosis (months)32.6 (3.3--168.0)93Median white blood cells at diagnosis × 10^3^/μL (range)29.2 (2.7--127.1)92Median count of hemoglobin92.1 (30.0--143.0)92Median monocyte at diagnosis × 10^3^/μL (range)5.2 (1.0--48.1)92Median platelet count at diagnosis × 10^3^/μL (range)73.3 (4.0--357.0)92Myeloid or erythroid precursors on PB smear (%)5.0 (0--24.0)81Median percentage of BM blasts at diagnosis (%)7.8 (0.4--20.0)83Median percentage of HbF at diagnosis21.0 (1.5--64.50)44Lactic dehydrogenase (U/L)936.0 (280.0--4200.0)43Monosomy 7 (*N*)12 (20.7%)58Abnormal karyotype (*N*)21 (33.8%)62HSCT (*N*)45 (48.4%)93RAS-signaling genes (*N*)93*PTPN11*30 (32.3%)*NF1*20 (21.5%)*NRAS*16 (17.2%)*KRAS*10 (10.8%)*CBL*4 (4.3%) Other13 (13.9%)Germline or somatic mutations93 Germline4/93 (4.30%) Somatic89/93 (95.7%)Number of somatic alterations at diagnosis (*N*)93 0 or 161 (65.6%) 2 or more32 (34.4%)Mutation subtypes stratified by *PTPN11* status and alteration number (*N*)93 Only one non-*PTPN11* mutation41 (44.1%) Only one *PTPN11* mutation14 (15.1%) Combined mutations without *PTPN11*20 (21.5%)*PTPN11* mutation with additional alterations18 (19.3%)

After diagnosis, we recommended swift HSCT for all children with *NF1*, somatic *PTPN11*, or *KRAS* mutations, and for the vast majority of children with somatic *NRAS* mutations. Children with *CBL* mutations were followed closely and were not offered HSCT immediately. Transplantation was considered, however, if disease progressed. Yet some patients did not receive HSCT due to fee or some other reasons. Forty-five patients received transplantation in 2--3 months after diagnosis. Thirty-two patients received mild chemotherapy before transplantation, with 15 receiving hydroxycarbamide, 8 receiving 6-mercaptopurine, 3 receiving 13-cis retinoic acid, and 6 receiving combined chemotherapy of these drugs. And 4 patients received courses of intensive chemotherapy for AML, 2 with daunorubicin-cytarabine-etoposide, and 2 with homoharringtonine-cytarabine. Five patients received decitabine before HSCT. The other 48 patients did not receive HSCT. Among these cases, only 2 patients of these cases received recorded chemotherapy, 1 with 13-cis retinoic acid, and 1 with a course of daunorubicin-cytarabine-etoposide before death.

After a median follow-up of 25 (0--125) months, 51 children were alive; By the Kaplan-Meier method, the 5 -year

OS was estimated at 50.7%. In the untransplanted patients, 9 cases died of primary disease due to lack of treatment and 1 died of transformation to AML. In the HSCT patients,7 cases died of relapse, 4 died of transplantation complications, and 2 died of AML. Relapse remained the major cause of death in JMML after HSCT. Some other studies have assigned poorer prognostic significance to several clinical and laboratory characteristics in patients with JMML, such as age \> 24 months, male sex, lower platelet count, and monosomy 7 \[[@CR12], [@CR13]\]. However, in our cohort, no clinical characteristics, including age, sex, platelet count, higher hemoglobin F (HbF) concentration for age, abnormal G-band karyotype of chromosome, and monosomy 7 detected by fluorescence in situ hybridization, reached significance in univariate Cox analysis (Table [3](#Tab3){ref-type="table"}).Table 3Univariate analysis of the EFS analysis in childhood JMMLVariable*N*/totalEFS (%)HR (95% CI)*P*Gender Female32/9348.41 Male61/9344.61.15 (0.62--2.11)0.659Age at diagnosis ≤ 24 months50/9353.51 \> 24 months43/9334.21.43 (0.81--2.54)0.217Platelet count at diagnosis (× 10^3^/μL) ≥ 4059/9245.71 \< 4033/9243.81.30 (0.72--2.33)0.389Myeloid or erythroid precursors on PB smear No17/8137.21.01 (0.54--1.87) Yes64/8148.00.99 (0.46--2.16)0.987HbF at diagnosis Not elevated for age7/4571.41 Elevated for age38/4546.92.28 (0.53--9.83)0.27Monosomy 7 Negative47/5943.91 Positive12/5965.60.51 (0.17--1.45)0.208Karyotype Normal41/6248.51 Abnormal21/6240.81.09(0.54--2.25)0. 796Germline or somatic mutation Germline4/9366.71 Somatic89/9344.01.53 (0.21--11.15)0.675*NF1* status Mutation absent67/9345.01 Mutation present26/9343.01.01 (0.54--1.87)0.988*PTPN11* status Mutation absent55/9357.41 Mutation present38/9327.22.25 (1.27--3.99)*0.005*Somatic alterations at diagnosis 0 or 161/9356.41 2 or more32/9325.02.13 (1.21--3.76)*0.009*HSCT Yes45/9354.11 No48/9333.61.95 (1.09--3.47)*0.024*Clinical and laboratory characteristics of 93 cases, including sex, age, platelet count, myeloid or erythroid precursors on PB smear, HbF concentration, monosomy 7, abnormal karyotype, somatic mutations, and *NF1* mutations, showed no prognostic significance in patients with JMML. *PTPN11* mutation and the number of somatic alterations present at diagnosis both appeared statistical significance for EFS. HSCT could improve the outcome in JMML significantly. *P* values \< 0.05% are shown in italics

Moreover, when the patients were divided into group with HSCT and group without HSCT, no relationship was found between these characteristics and disease outcome except age (*P* = 0.008) (Table [4](#Tab4){ref-type="table"}). Patients with HSCT showed no differences in sex, platelet count, elevated HbF concentration for age, karyotype, monosomy 7 status, mutation genes, and the number of alterations in comparison with patients without HSCT (*P* \> 0.05). But the HSCT group was enriched with patients older than 24 months in comparison with the no-HSCT group (*P* = 0.031).Table 4Univariate analysis of the EFS in JMML when the patients divided into HSCT and no-HSCT groupVariableHSCT cases (*N* = 45)no-HSCT cases (*N* = 48)*N*/totalEFS (%)HR (95% CI)*PN*/total = 48EFS (%)HR (95% CI)*P*Gender Female15/4553.3117/4842.51 Male30/4554.30.84 (0.33--2.10)0.70631/4826.71.54 (0.68--3.51)0.287Age at diagnosis ≤ 24 months19/4583.9131/4828.51 \> 24 months26/4532.65.36 (1.56--18.39)***0.008***17/4838.80.85 (0.39--1.84)0.67Platelet count at diagnosis (× 10^3^/μL) ≥ 4030/4552.2129/4737.61 \< 4015/4559.31.05 (0.40--2.73)0.92618/4730.91.47 (0.69--3.15)0.318Myeloid or erythroid precursors on PB smear No8/4343.819/3829.21 Yes35/4359.30.72 (0.23--2.16)0.54829/3833.91.44 (0.49--4.27)0.509Fetal hemoglobin at diagnosis ≤ 10%5/2980.012/16501 \> 10%24/2952.62.88 (0.37--22.35)0.31114/1635.81.58 (0.19--12.97)0.672Monosomy 7 Negative24/3354.2123/2633.21 Positive9/3388.90.22 (0.03--1.71)0.1473/2601.58 (0.46--5.48)0.469Karyotype Normal20/3458.2121/2839.41 Abnormal14/3457.10.96 (0.33--2.77)0.9387/2801.70 (0.64--4.54)0.289*NF1* status Mutation absent29/4560.0138/4832.21 Mutation present16/4543.81.65 (0.69--3.40)0.26410/4843.80.73 (0.28--1.94)0.532*PTPN11* status Mutation absent24/4565.2131/4849.81 Mutation present21/4542.91.72 (0.70--4.22)0.23317/486.43.70 (1.71--8.00)*0.001*Somatic alterations at diagnosis 0 or 127/4569.2134/4843.41 2 or more18/4533.32.57(1.05--6.29)***0.039***14/4814.32.07 (0.98--4.39)0.058Mutation subtype Only one non-*PTPN11* mutation16/4567.7125/4854.61 Only one *PTPN11* mutation11/4572.70.68 (0.16--2.84)0.5959/4813.33.77 (1.36--10.44)*0.011* Combined mutations without *PTPN11*8/4562.51.01 (0.24--4.22)0.9946/4833.31.79 (0.55--5.82)0.336*PTPN11* mutation with additional alterations10/4510.03.60 (1.20--10.79)***0.022***8/4804.44 (1.68--11.78)*0.003P* values \< 0.05% are shown in italics

Expanding the spectrum of RAS-pathway mutations {#Sec9}
-----------------------------------------------

Although RAS-pathway lesions have traditionally been thought to represent largely mutually exclusive events \[[@CR12]\], coexisting mutations in *NRAS*, *KRAS*, *PTPN11*, *CBL*, and *NF1* were found in 10 of 93 (10.8%) patients, 3 with *PTPN11* and *NF1*, 2 with *PTPN11* and *CBL*, 1 with *PTPN11* and *NRAS*, 1 with *NF1* and *NRAS*, 1 with *NF1* and *KRAS*, 1 with *PTPN11* and *NRAS* and *KRAS*, and 1 with *PTPN11* and *NRAS* and *CBL.* Acquisition of *NF1* haploinsufficiency with *PTPN11* was the most frequent subclone event. No significant difference in EFS was noted among the five RAS-signaling genes (*P* = 0.123) (Fig. [1a](#Fig1){ref-type="fig"}). No difference was found between germline and somatic mutation either (EFS 66.7% vs. 44.0%, hazard ratio (HR) = 1.53, confidence interval (CI) = 0.21--11.15, *P* = 0.675) (Table [3](#Tab3){ref-type="table"}).Fig. 1The EFS and genotype in JMML. **a** EFS based on the type of the five classical RAS-signaling genes. No significant difference was noted. **b** EFS based on status of *PTPN11*. Patients with *PTPN11* mutation exhibited significantly lower EFS compared with non-*PTPN11* mutations. **c** EFS based on the number of somatic events. Patients without or with one somatic alteration at diagnosis showed significantly better prognosis in comparison to those with more than two alterations. **d** EFS based on the four subgroups stratified by the mutational gene and number. *PTPN11* mutation with additional alteration exhibited poorer outcome when compared with other three subtypes, only one non-*PTPN11* mutation, only one *PTPN11* mutation, and combined mutations without *PTPN11*.

However, patients with *PTPN11* mutation exhibited significantly lower EFS compared with non-*PTPN11* mutations (EFS 27.2% vs. 57.4%, HR = 2.25, CI = 1.27--3.99, *P* = 0.005) (Fig. [1b](#Fig1){ref-type="fig"}). There were no differences in age, sex, distribution of clinical parameters, and HSCT treatment in patients with *PTPN11* or non-*PTPN11* mutations (*P* \> 0.05).

The secondary mutational signature correlating with disease aggressiveness {#Sec10}
--------------------------------------------------------------------------

In addition to the classical JMML-associated mutations affecting RAS-pathway genes (*PTPN11*, *NF1*, *KRAS*, *NRAS*, and *CBL*), gene sequencing detected secondary mutations in *ASXL1* (7/93, 7.5%), *JAK3* (6/93, 6.4%), *SETBP1* (4/93, 4.3%), *EZH2* (2/93, 2.2%), *JAK2* (1/93, 1.1%), *SRSF2* (1/93, 1.1%), *GATA2* (1/93, 1.1%), and *NOTCH1* (1/93, 1.1%), many of which were known epigenetic modifiers including members of the polycomb repressive complex 2 (PRC2) or genes implicated in RAS-RAF-MEK-ERK pathway activation.

Five of the six patients with *JAK3* mutations at diagnosis co-occurred with *PTPN11* mutations and all six patients went on to poor outcome, uncovering activated JAK-STAT corresponding with clinical outcome.

We identified a mutation in *GATA2*, a transcription factor broadly involved in hematopoiesis \[[@CR18]\] and a mutation in *SRSF2*, a member of the spliceosome complex. Recent work has shown that germline *GATA2* mutations are responsible for several syndromes, leading to a predisposition to myeloid malignancies \[[@CR7], [@CR9]\].

In contrast to previous reports that emphasized the rarity of genetic mutations in epigenetic modifier genes in JMML \[[@CR8], [@CR19], [@CR22]\], we identified components of PRC2, including *EZH2* and *ASXL1*, were mutated at diagnosis (9/93, 9.68%). Mutations in epigenetic modifiers are frequent in JMML.

Somatic alterations at diagnosis predicting outcome {#Sec11}
---------------------------------------------------

Using the number of somatic events at diagnosis, we evaluated differences in prognosis. In our 93-patient cohort, patients without or only with one somatic alteration at diagnosis showed significantly better prognosis in comparison with those with more than two alterations (EFS 56.4% vs. 25.0%, HR = 2.13, CI = 1.21--3.76, *P* = 0.009) (Fig. [1c](#Fig1){ref-type="fig"}).

HSCT could improve the EFS and OS significantly (EFS 54.1% vs. 33.6%, HR = 1.95, CI = 1.09--3.47, *P* = 0.024 and OS 66.8% vs. 33.6%, HR = 3.09, CI = 1.67--5.85, *P* \< 0.0001) compared with patients without HSCT (Fig. [2](#Fig2){ref-type="fig"}). Although most of patients received chemotherapy before HSCT, we thought it was not beneficial to the final outcome because intensity of chemotherapy (non-, mild, or AML-like) prior to HSCT did not induce remission and showed no impact on HSCT outcome (*P* = 0.767), being not in favor of intense chemotherapy before transplantation, to avoid the adverse reactions associated with intense chemotherapy.Fig. 2HSCT can improve the EFS and OS in JMML significantly

The OS of no-HSCT patients in our study was better than some other reports, maybe because this group was enriched with more *KRAS* (11/43, 25.6%) and *CBL* (4/43, 9.3%) mutations, 1 germline mutation in *PTPN11*, and 1 germline mutation in *NF1*.

Furthermore, when a Cox multivariate regression model was applied, *PTPN11* mutation remained independently prognostic of poor outcome (EFS HR = 2.57, CI = 1.41--4.69, *P* = 0.002) after adjusting for the number of alterations and HSCT treatment. Two or more somatic events also remained independently prognostic of poor prognosis (EFS HR = 2.05, CI = 1.15--3.67, *P* = 0.015) after adjusting for *PTPN11* status and HSCT (Table [5](#Tab5){ref-type="table"}). Not only *PTPN11* mutation but also the number of somatic alterations at diagnosis retained statistical significance for EFS.Table 5Multivariate analysis of the survival parameters in JMMLVariable*N*EFS (%)HR (95% CI)*PPTPN11* status Mutation absent5557.41 Mutation present3827.22.57 (1.41--4.69)*0.002*Somatic alterations at diagnosis 0 or 16156.41 2 or more3225.02.05 (1.15--3.67)*0.015*HSCT Yes4554.11 No4833.62.66 (1.46--4.84)*0.001*Mutation subtype Only one non-*PTPN11* mutation4160.91 Only one *PTPN11* mutation2047.81.63 (0.71--3.72)0.246 Combined mutations without *PTPN11*1450.01.32 (0.53--3.31)0.556*PTPN11* mutation with additional alterations185.63.88 (1.87--8.05)***\<*** *0.0001*When a Cox multivariate regression model was applied, *PTPN11* mutation and the number of somatic alterations remained independently prognostic of poor outcome after adjusting for the improvement of HSCT treatment. Then, the cohort was subdivided. *PTPN11* mutation with additional alteration showed the poorest outcome in comparison with those with only one non-*PTPN11* mutation, only one *PTPN11* mutation, and combined mutations without *PTPN11*. HSCT could improve the outcome significantly. *P* values \< 0.05% are shown in italics

On account of the relevance between *PTPN11* status and the number of mutations (*P* = 0.029) and some patients harboring both characteristics, 93 cases were then subdivided into four groups stratified by their mutational gene and number, only one non-*PTPN11* mutation (41/93, 44.0%), only one *PTPN11* mutation (20/93, 21.5%), combined mutations but without *PTPN11* abnormity (14/93, 15.1%), and *PTPN11* mutation with additional somatic alteration (18/93, 19.4%). The *PTPN11*-mutated subgroup of patients showed the shortest survival which worsened when a secondary mutation was present (EFS 5.6%, HR = 3.73, CI = 1.83--7.62, *P* \< 0.0001). The subgroup of only one *PTPN11* mutation (EFS 47.8%, HR = 1.45, CI = 0.64--3.27, *P* = 0.369) and the subgroup holding combined mutations, but excluding *PTPN11* abnormity (EFS 50.0%, HR = 1.27, CI = 0.51--3.14, *P* = 0.610), exhibited a little more hazard compared with the subtype of only one non-*PTPN11* mutation (EFS 60.9%), albeit no statistically significant difference (Fig. [1d](#Fig1){ref-type="fig"}).

Discussion {#Sec12}
==========

JMML is characterized by the presence of mutations activating the RAS-signaling pathway in about 90% of cases \[[@CR1], [@CR6]\], in which the mutation of *PTPN11* is a marker of poor prognosis. Recent studies have shown that oncogenic RAS signaling can mediate genomic DNA methylation \[[@CR6], [@CR11], [@CR21]\]. RAS-activating mutations in different genes might have distinct effects on epigenome remodeling. Analyzing 167 cases, the EWOG-MDS demonstrated that the low-methylation cluster comprised patients with *CBL* and *NRAS* mutations known to have a favorable prognosis. *KRAS* mutation was associated with the intermediate cluster. The high methylation group was dominated by cases with *PTPN11* mutation, resulting in poor outcome, suggesting RAS-pathway mutation patterns define epigenetic subclasses in JMML \[[@CR10]\]. In addition, hinting at possible functional links between Ras activation and methylation classes, some research also reported that DNA hypermethylation was more pronounced when additional mutations in Ras-pathway genes or epigenetic modifier genes were present \[[@CR10], [@CR17]\].

Furthermore, we have shown that secondary mutations providing additional activation of RAS-signaling and other signaling pathways were frequent in poor-outcome JMML. It seemed that these secondary mutations, as second hits targeting the RAS pathway, contribute to further augment the extent of epigenetic remodeling. Pre-existing epigenetic alterations might provide a fertile ground for malignant transformation following single or few genetic hits. This sequence of events has been shown in lung cancer where hypermethylation of PRC2 target genes sensitizes epithelial cells to single-step transformation by mutant *KRAS* \[[@CR24]\]. No matter whether the RAS-signaling genes or the so-called secondary mutations are primary to drive disease, it implies that each mutation in a series of mutations has biological activity, more mutations, more hits, thus maybe more aggressive.

In our cohort, DNA was extracted from PB or BM. The mutation frequencies in PB or BM were still comparable because leukemia cells could distribute in both PB and BM with almost the same proportion in JMML other than the predominant rate in BM in acute leukemia. Thus, the outcome determined by the mutation patterns was not biased regardless of sample sources.

In conclusion, both *PTPN11* mutation and the number of somatic alterations detected at diagnosis are likely to be the major determinant of outcome in JMML. Notably, in addition to identifying patients with aggressive disease, our data provides patient selection criteria for therapeutic options in this heterogeneous childhood leukemia. Yet, the effects of RAS-signaling genes on epigenome remodeling and the interactions of these secondary events in RAS-signaling and other signaling pathways remain to be explored.
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Authors' summary: We found that both *PTPN11* mutation and the number of somatic alterations detected at diagnosis are likely to be the major determinant of outcome in JMML. Moreover, the subgroup of patients with *PTPN11* mutation showed the shortest survival which even worsened when a secondary mutation was present. Notably, in addition to identifying patients with aggressive disease, our data expanded mutational spectrum on the pathogenesis of JMML, providing functional guidance, prognostic markers, and patient selection criteria for therapeutic options in this heterogeneous childhood leukemia.
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